Radioiodinated agents for imaging multidrug resistant tumors

Zbigniew P. Kortylewicz, Ann M. Augustine, Jessica Nearman, Jonathon McGarry, Janina Baranowska-Kortylewicz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Diagnostic agents enabling characterization of multidrug resistance (MDR) in tumors can aid in the selection of chemotherapy regimens. We report here synthesis and evaluation of radiopharmaceuticals based on the second-generation MDR-reversing drug MS-209. 5-[3-{4-(2-Phenyl-2- (4′-[125I] iodo-phenyl)acetyl) piperazin-1-yl} -2-hydroxypropoxy]quinoline (17) was prepared from the 4′-tributylstannyl precursor (16) in >95% radiochemical yield. (16) was synthesized in a six-step process with the overall yield of 25%. In vitro studies were conducted in MES-SA (drug-sensitive) and MES-SA/Dx5 (MDR) human uterine sarcoma cell lines. In vivo studies were performed in athymic mice bearing MES-SA and MES-SA/Dx5 xenografts. The uptake of (17) is higher in MES-SA than MES-SA/Dx5 cells. The uptake and efflux of (17) depend on temperature and concentration, and indicate active transport mechanism(s). Incubation of drug sensitive MES-SA cells with verapamil or (15), a nonradioactive analog of (17), alters the cellular retention of radioactivity only marginally. However, MES-SA/Dx5 cells retain ∼12% more of (17) when incubated with 10 μM verapamil. The addition of (15) or high concentrations of (17) also increase the uptake of (17) in MES-SA/Dx5 up to 200%, depending on the concentration and temperature. The dependence of (17) uptake on the MDR status is also evident in the ex vivo binding studies. In vivo tests in mice xenografted simultaneously with both tumor cell lines indicate distinct pharmacokinetics for each tumor. The absorption half-life in MES-SA/Dx5 xenograft is ∼10× shorter and the mean residence time ∼50% shorter compared to MES-SA xenograft in the same mouse. Radioiodinated derivatives of MS-209 appear to be good indicators of multidrug resistance.

Original languageEnglish (US)
Pages (from-to)171-181
Number of pages11
JournalMedicinal Chemistry
Volume5
Issue number2
DOIs
StatePublished - Sep 18 2009

Fingerprint

Multiple Drug Resistance
Heterografts
Neoplasms
Verapamil
Pharmaceutical Preparations
Temperature
Radiopharmaceuticals
Active Biological Transport
Tumor Cell Line
Nude Mice
Sarcoma
Radioactivity
Half-Life
Pharmacokinetics
Drug Therapy
Cell Line
dofequidar

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Radioiodinated agents for imaging multidrug resistant tumors. / Kortylewicz, Zbigniew P.; Augustine, Ann M.; Nearman, Jessica; McGarry, Jonathon; Baranowska-Kortylewicz, Janina.

In: Medicinal Chemistry, Vol. 5, No. 2, 18.09.2009, p. 171-181.

Research output: Contribution to journalArticle

Kortylewicz, Zbigniew P. ; Augustine, Ann M. ; Nearman, Jessica ; McGarry, Jonathon ; Baranowska-Kortylewicz, Janina. / Radioiodinated agents for imaging multidrug resistant tumors. In: Medicinal Chemistry. 2009 ; Vol. 5, No. 2. pp. 171-181.
@article{507d546c2c68490193f1db2493560866,
title = "Radioiodinated agents for imaging multidrug resistant tumors",
abstract = "Diagnostic agents enabling characterization of multidrug resistance (MDR) in tumors can aid in the selection of chemotherapy regimens. We report here synthesis and evaluation of radiopharmaceuticals based on the second-generation MDR-reversing drug MS-209. 5-[3-{4-(2-Phenyl-2- (4′-[125I] iodo-phenyl)acetyl) piperazin-1-yl} -2-hydroxypropoxy]quinoline (17) was prepared from the 4′-tributylstannyl precursor (16) in >95{\%} radiochemical yield. (16) was synthesized in a six-step process with the overall yield of 25{\%}. In vitro studies were conducted in MES-SA (drug-sensitive) and MES-SA/Dx5 (MDR) human uterine sarcoma cell lines. In vivo studies were performed in athymic mice bearing MES-SA and MES-SA/Dx5 xenografts. The uptake of (17) is higher in MES-SA than MES-SA/Dx5 cells. The uptake and efflux of (17) depend on temperature and concentration, and indicate active transport mechanism(s). Incubation of drug sensitive MES-SA cells with verapamil or (15), a nonradioactive analog of (17), alters the cellular retention of radioactivity only marginally. However, MES-SA/Dx5 cells retain ∼12{\%} more of (17) when incubated with 10 μM verapamil. The addition of (15) or high concentrations of (17) also increase the uptake of (17) in MES-SA/Dx5 up to 200{\%}, depending on the concentration and temperature. The dependence of (17) uptake on the MDR status is also evident in the ex vivo binding studies. In vivo tests in mice xenografted simultaneously with both tumor cell lines indicate distinct pharmacokinetics for each tumor. The absorption half-life in MES-SA/Dx5 xenograft is ∼10× shorter and the mean residence time ∼50{\%} shorter compared to MES-SA xenograft in the same mouse. Radioiodinated derivatives of MS-209 appear to be good indicators of multidrug resistance.",
author = "Kortylewicz, {Zbigniew P.} and Augustine, {Ann M.} and Jessica Nearman and Jonathon McGarry and Janina Baranowska-Kortylewicz",
year = "2009",
month = "9",
day = "18",
doi = "10.2174/157340609787582954",
language = "English (US)",
volume = "5",
pages = "171--181",
journal = "Medicinal Chemistry",
issn = "1573-4064",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Radioiodinated agents for imaging multidrug resistant tumors

AU - Kortylewicz, Zbigniew P.

AU - Augustine, Ann M.

AU - Nearman, Jessica

AU - McGarry, Jonathon

AU - Baranowska-Kortylewicz, Janina

PY - 2009/9/18

Y1 - 2009/9/18

N2 - Diagnostic agents enabling characterization of multidrug resistance (MDR) in tumors can aid in the selection of chemotherapy regimens. We report here synthesis and evaluation of radiopharmaceuticals based on the second-generation MDR-reversing drug MS-209. 5-[3-{4-(2-Phenyl-2- (4′-[125I] iodo-phenyl)acetyl) piperazin-1-yl} -2-hydroxypropoxy]quinoline (17) was prepared from the 4′-tributylstannyl precursor (16) in >95% radiochemical yield. (16) was synthesized in a six-step process with the overall yield of 25%. In vitro studies were conducted in MES-SA (drug-sensitive) and MES-SA/Dx5 (MDR) human uterine sarcoma cell lines. In vivo studies were performed in athymic mice bearing MES-SA and MES-SA/Dx5 xenografts. The uptake of (17) is higher in MES-SA than MES-SA/Dx5 cells. The uptake and efflux of (17) depend on temperature and concentration, and indicate active transport mechanism(s). Incubation of drug sensitive MES-SA cells with verapamil or (15), a nonradioactive analog of (17), alters the cellular retention of radioactivity only marginally. However, MES-SA/Dx5 cells retain ∼12% more of (17) when incubated with 10 μM verapamil. The addition of (15) or high concentrations of (17) also increase the uptake of (17) in MES-SA/Dx5 up to 200%, depending on the concentration and temperature. The dependence of (17) uptake on the MDR status is also evident in the ex vivo binding studies. In vivo tests in mice xenografted simultaneously with both tumor cell lines indicate distinct pharmacokinetics for each tumor. The absorption half-life in MES-SA/Dx5 xenograft is ∼10× shorter and the mean residence time ∼50% shorter compared to MES-SA xenograft in the same mouse. Radioiodinated derivatives of MS-209 appear to be good indicators of multidrug resistance.

AB - Diagnostic agents enabling characterization of multidrug resistance (MDR) in tumors can aid in the selection of chemotherapy regimens. We report here synthesis and evaluation of radiopharmaceuticals based on the second-generation MDR-reversing drug MS-209. 5-[3-{4-(2-Phenyl-2- (4′-[125I] iodo-phenyl)acetyl) piperazin-1-yl} -2-hydroxypropoxy]quinoline (17) was prepared from the 4′-tributylstannyl precursor (16) in >95% radiochemical yield. (16) was synthesized in a six-step process with the overall yield of 25%. In vitro studies were conducted in MES-SA (drug-sensitive) and MES-SA/Dx5 (MDR) human uterine sarcoma cell lines. In vivo studies were performed in athymic mice bearing MES-SA and MES-SA/Dx5 xenografts. The uptake of (17) is higher in MES-SA than MES-SA/Dx5 cells. The uptake and efflux of (17) depend on temperature and concentration, and indicate active transport mechanism(s). Incubation of drug sensitive MES-SA cells with verapamil or (15), a nonradioactive analog of (17), alters the cellular retention of radioactivity only marginally. However, MES-SA/Dx5 cells retain ∼12% more of (17) when incubated with 10 μM verapamil. The addition of (15) or high concentrations of (17) also increase the uptake of (17) in MES-SA/Dx5 up to 200%, depending on the concentration and temperature. The dependence of (17) uptake on the MDR status is also evident in the ex vivo binding studies. In vivo tests in mice xenografted simultaneously with both tumor cell lines indicate distinct pharmacokinetics for each tumor. The absorption half-life in MES-SA/Dx5 xenograft is ∼10× shorter and the mean residence time ∼50% shorter compared to MES-SA xenograft in the same mouse. Radioiodinated derivatives of MS-209 appear to be good indicators of multidrug resistance.

UR - http://www.scopus.com/inward/record.url?scp=65349145809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349145809&partnerID=8YFLogxK

U2 - 10.2174/157340609787582954

DO - 10.2174/157340609787582954

M3 - Article

VL - 5

SP - 171

EP - 181

JO - Medicinal Chemistry

JF - Medicinal Chemistry

SN - 1573-4064

IS - 2

ER -